Skip to content
Medical Health Aged Care

Techcracker Lab Showcase: Breakthrough Medtech and Deep Tech at UNSW

UNSW Sydney < 1 mins read
Key Facts:

Techcracker event details

When: Friday 14 November, 2:00–5:15pm (Tech Expo and refreshments 5:15–6:30pm)

Where: Leighton Hall, John Niland Scientia Building, UNSW Kensington Campus

Cost: Free (registration essential)


UNSW Sydney and Horizons Ventures invite media to attend the Techcracker Lab showcase, a free event on Friday 14 November at UNSW’s Kensington campus.

The showcase will highlight breakthrough technologies and the visionary founders behind them, featuring live demonstrations from leading med-tech start-ups from Australia and abroad, including US-based HistoSonics, which will demonstrate its new FDA-approved histotripsy technology, a non-invasive therapy that destroys tumour tissue using pulsed sound waves.

Solina Chau, co-founder of Hong Kong-based venture capital firm Horizons Ventures and Director of the Li Ka Shing Foundation, will appear at the event alongside UNSW Chancellor David Gonski AC. The program will be hosted by Professor Bronwyn Fox AO, UNSW Deputy Vice-Chancellor (Research & Enterprise).

Speakers from Horizons Ventures' portfolio companies, including Harrison.ai, MEandMINE, Holoclara and HistoSonics, will share insights into how deep tech founders and investors navigate innovation, scale and global impact.

A key feature of Techcracker Lab is the Medtech Expo, showcasing UNSW’s most promising start-ups. As Australia’s number one university for founders, UNSW is proud to present ventures emerging from its world-class research and entrepreneurial ecosystem.


Contact details:

UNSW Sydney

Julia Holman, +61 435 124 673, [email protected]

H.S. Chau Foundation

Ryan Fung, +852 6683 1313, [email protected]

 

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.